Treatment and functional outcome of patients with cystoid macular edema: a single-center experience

详细信息    查看全文

• 作者：Mara Taraborelli ; Ilaria Cavazzana ; Micaela Fredi ; Paolo Airò…
• 关键词：Anti ; TNFα ; Cystoid macular edema ; Interferon ; α ; Uveitis
• 刊名：Clinical Rheumatology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：34
• 期：4
• 页码：791-794
• 全文大小：103 KB
• 参考文献：1. Bringmann, A, Reichenbach, A, Wiedemann, P (2004) Pathomechanisms of cystoids macular edema. Ophthalmic Res 36: pp. 241-249 CrossRef
  2. Scholl, S, Augustin, A, Loewenstein, A, Rizzo, S, Kuppermann, BD (2011) General pathophysiology of macular edema. Eur J Ophthalmol 21: pp. S10-S19 CrossRef
  3. Rothova, A (2007) Inflammatory cystoid macular edema. Curr Opin Ophthalmol 18: pp. 487-492 CrossRef
  4. Ossewaarde-van Norel, A, Rothova, A (2011) Clinical review: update on treatment of inflammatory macular edema. Ocul Immunol Inflamm 19: pp. 75-83 CrossRef
  5. Deuter, CME, Koetter, I, Guenaydin, I, Stuebiger, N, Zierhut, M (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26: pp. 786-791 CrossRef
  6. Theossiadis, PG, Markomichelakis, NN, Sfikakis, PP (2007) Tumor necrosis factor antagonists. Preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27: pp. 399-413 CrossRef
  Criteria for diagnosis of Beh?et’s disease. Lancet 335: pp. 1078-1080
  The International Criteria for Beh?et’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28: pp. 338-347 CrossRef
  7. Deuter, CM, Koetter, I, Guenaydin, I, Stuebiger, N, Zierhut, M (2006) Interferon alfa-2A: a new treatment option for long lasting refracorty cystoid macular edema in uveitis?. Retina J Retina And Vitreous Dis 7: pp. 787-791
  8. Lardenoye, CW, Kooij, B, Rothova, A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmol 113: pp. 1446-1449 CrossRef
  9. Deuter, CM, K?tter, I, Günaydin, I (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoids macular oedema due to non-infectious uveitis. Br J Ophthalmol 93: pp. 906-913 CrossRef
  10. Paire, V, Lebreton, O, Weber, M (2010) Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/or immunosuppressive treatment. J Fr Ophtalmol 33: pp. 152-162 CrossRef
  11. Butler, NJ, Suhler, EB, Rosenbaum, JT (2012) Interferon alpha 2b in the treatment of uveitic cystoids macular edema. Ocul Immunol Inflamm 20: pp. 86-90 CrossRef
  12. Markomichelakis, NN, Theodossiadis, PG, Pantelia, E (2004) Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 138: pp. 648-650 CrossRef
  13. Theodossiadis, PG, Markomichelakis, NN, Sfikakis, PP (2007) Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27: pp. 399-413 CrossRef
  14. Schaap-Fogler, M, Amer, R, Friling, R, Priel, E, Kramer, M (2014) Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol 252: pp. 633-640 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  
• 出版者：Springer London
• ISSN：1434-9949

文摘

The aim of this study was to describe a single-center experience in the treatment and follow-up of cystoid macular edema patients. Clinical records of all patients with cystoid macular edema followed up in the Rheumatologic and Ophthalmological Unit of our center between 1993 and 2013 were retrospectively evaluated. The outcome was assessed by visual acuity and optical coherence tomography status during follow-up. Comparisons were made by Fisher’s exact test (p--.05 significant). In this study 16 eyes in 9 patients were analyzed. Our study includes mainly post-uveitic (78?%) cases with a high prevalence of human leukocyte antigen B51 (67?%). Systemic immunosuppressive therapy was prescribed in 87?% of cases. The most frequently used drugs were cyclosporine, interferon-α, and infliximab. The first two molecules appeared respectively the most used as the first option and the one with the longest survival on treatment. Interferon-α was the most effective drug in contrasting visual acuity loss compared to the majority of drugs, but significantly more effective than mycophenolate (p--.01) in reducing macular edema. At the end of follow-up, 50?% of patients showed a significant visual loss, while 88?% did not present macular edema. In our small cohort, interferon-α is the most promising drug in contrasting visual acuity loss in cystoid macular edema. Visual prognosis remains severe in these patients.